Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 494441 - 494460 out of 505060 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| USA | (L01EA01) imatinib (adm: O) | GLEEVEC 400MG | 30 | Ex-factory price without vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma;Gastrointestinal Stromal Tumors;Dermatofibrosarcoma;Myelodysplastic-Myeloproliferative Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Hypereosinophilic Syndrome | NovartisPharmaceuticalsCorporation |
| USA | (L01EA01) imatinib (adm: O) | GLEEVEC 400MG | 30 | Ex-factory price without vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma;Gastrointestinal Stromal Tumors;Dermatofibrosarcoma;Myelodysplastic-Myeloproliferative Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Hypereosinophilic Syndrome | NovartisPharmaceuticalsCorporation |
| USA | (L01EA01) imatinib (adm: O) | GLEEVEC 100MG TAB | 90 | Ex-factory price without vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma;Gastrointestinal Stromal Tumors;Dermatofibrosarcoma;Myelodysplastic-Myeloproliferative Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Hypereosinophilic Syndrome | NovartisPharmaceuticalsCorporation |
| USA | (L01EA01) imatinib (adm: O) | GLEEVEC 100MG TAB | 90 | Ex-factory price without vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma;Gastrointestinal Stromal Tumors;Dermatofibrosarcoma;Myelodysplastic-Myeloproliferative Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Hypereosinophilic Syndrome | NovartisPharmaceuticalsCorporation |
| USA | (L01EA03) nilotinib (adm: O) | TASIGNA 150MG CAP | 112 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA03) nilotinib (adm: O) | TASIGNA 150MG CAP | 112 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA03) nilotinib (adm: O) | TASIGNA 200MG CAP | 112 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA03) nilotinib (adm: O) | TASIGNA 200MG CAP | 112 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA03) nilotinib (adm: O) | TASIGNA 50MG CAP,ORAL | 120 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA03) nilotinib (adm: O) | TASIGNA 50MG CAP,ORAL | 120 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA06) asciminib (adm: O) | SCEMBLIX 100MG TAB | 60 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA06) asciminib (adm: O) | SCEMBLIX 100MG TAB | 60 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA06) asciminib (adm: O) | SCEMBLIX 20MG TAB | 60 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA06) asciminib (adm: O) | SCEMBLIX 20MG TAB | 60 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA06) asciminib (adm: O) | SCEMBLIX 40MG TAB | 60 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EA06) asciminib (adm: O) | SCEMBLIX 40MG TAB | 60 | Ex-factory price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaceuticalsCorporation |
| USA | (L01EC02) dabrafenib (adm: O) | TAFINLAR 50MG CAP | 120 | Ex-factory price without vat |
$0-0 |
$0-0 |
Melanoma | NovartisPharmaceuticalsCorporation |
| USA | (L01EC02) dabrafenib (adm: O) | TAFINLAR 50MG CAP | 120 | Ex-factory price without vat |
$0-0 |
$0-0 |
Melanoma | NovartisPharmaceuticalsCorporation |
| USA | (L01EC02) dabrafenib (adm: O) | TAFINLAR 75MG CAP | 120 | Ex-factory price without vat |
$0-0 |
$0-0 |
Melanoma | NovartisPharmaceuticalsCorporation |
| USA | (L01EC02) dabrafenib (adm: O) | TAFINLAR 75MG CAP | 120 | Ex-factory price without vat |
$0-0 |
$0-0 |
Melanoma | NovartisPharmaceuticalsCorporation |
Pages
